A new cell therapy for certain autoimmune diseases
Treatments studied
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This study tests a new treatment called CTX112, which uses modified immune cells to target and calm the immune system. It is for people with certain autoimmune diseases that have not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 69 years old.
- You must weigh more than 40 kilograms (about 88 pounds).
- You must have a confirmed diagnosis of one of these conditions: stiff person syndrome, relapsing neuromyelitis optica spectrum disorder, relapsing MOG antibody disease, refractory autoimmune encephalitis, or refractory stiff person syndrome.
- Your major organs (like blood, kidneys, liver, heart, and lungs) must be working well enough.
- You must be willing to use effective birth control if you or your partner can become pregnant.
- You must not have had a gene therapy or a transplant of solid organs or blood-forming cells before.
- You must not have certain active infections or a history of cancer in the last 5 years.
- You must not have a history of suicide attempts in the last 3 years.
- You must be able to undergo MRI scans and lumbar punctures (spinal taps).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
This trial tests a new immune-cell therapy (CAR-T) for people with certain autoimmune diseases of the brain and spinal cord that have not improved with standard treatments. The therapy aims to reset the immune system to stop it from attacking the nervous system.
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD19 and BCMA proteins on B cells. It is for people with certain neurological autoimmune diseases that have come back or not responded to standard treatments. The goal is to see if this therapy can help control the disease.
This trial tests a treatment called CNCT19, a type of CAR-T cell therapy, for people with certain autoimmune diseases like neuromyelitis optica, myasthenia gravis, or multiple sclerosis that have come back or not responded to other treatments. It aims to see if targeting a specific immune cell (CD19) can help control the disease.
This early-stage trial uses a type of immune cell therapy (CAR-T cells) to treat severe autoimmune diseases that attack the nervous system, such as NMOSD, myasthenia gravis, CIDP, and multiple sclerosis. The goal is to see if this treatment can stop the immune system from damaging nerves when other treatments have failed.
This early-phase trial tests a new type of immune cell therapy (CAR-T) designed to target and calm the immune system in people with certain autoimmune neurological diseases that haven't improved with standard care. The goal is to see if it's safe and if it can reduce disease activity.
Hear when a new Neuromyelitis Optica trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.